ClinicalTrials.gg
RecruitingNCT07489131ALVOEYE-HDUpdated Apr 30, 2026

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

A Phase 3 interventional study of AVT29 (proposed aflibercept HD biosimilar) and Eylea HD (aflibercept HD) in Diabetic Macular Edema, sponsored by Alvotech Swiss AG. Recruiting at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Macular Edema with a site in Hungary — 2 open to participants now, 5 under way, 3 of them phase 3. Macular Edema · Hungary.

Planned enrollment
26th of 37
256 · median 406
Started
2026
with 1 other
Phase 3
28 of 39
1 open now
Registered
39th of 39
by date
Lead sponsor
1 of 39
Alvotech Swiss AG

Among the 39 studies in Macular Edema with a site in Hungary, this one is the 26th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 in phase 3, and was the 39th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

2 of the 39 studies in Macular Edema with a site in Hungary are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Macular Edema with a site in Hungary, or all of them as a file.
02

Study summary

This is a Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea HD in Participants with Diabetic Macular Edema.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Participant is ≥18 years old at the time of signing the ICF.
  • Participant is willing and able to comply with all study procedures and likely to complete the study, based on the investigator's judgment.
  • Participant has a diagnosis of DME secondary to DM with central involvement in the study eye.
  • Participant has a BCVA ETDRS letter score of 73 to 34 letters inclusive (20/40 to 20/200 Snellen equivalent) in the study eye at screening and on Day 1 prior randomization.
  • Participant's decrease in vision is determined to be primarily the result of DME in the study eye.

Main Exclusion Criteria:

  • previous treatment with anti-VEGF therapy
  • history or concurrent disease other than DME that could compromise visual acuity
  • Any condition that, in the Investigator ́s opinion, can interfere with full participation in the study, including administration of the study treatment and attending required visits; can pose a significant risk to the participant, or interfere with interpretation of study data
  • participants not suitable for participation, whatever the reason, as judged by the Investigator, including medical or psychiatric conditions, or participants potentially at risk of noncompliance to study procedures.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
256 participants (estimated)

Study arms

  • Experimental
    AVT29 (proposed aflibercept HD biosimilar)

    Participants will receive 1 IVT injection of AVT29 at baseline and every 4 weeks for 2 consecutive monthly visits (at Week 4 and Week 8), followed by 1 IVT injection every 8 to 16 weeks based on DRM criteria through study completion.

    Drug: AVT29 (proposed aflibercept HD biosimilar)

  • Active comparator
    Eylea HD (aflibercept HD)

    Participants will receive 1 IVT injection of Eylea HD at baseline and every 4 weeks for 2 consecutive monthly visits (at Week 4 and Week 8), followed by 1 IVT injection every 8 to 16 weeks based on DRM criteria through study completion.

    Drug: Eylea HD (aflibercept HD)

Interventions

  • DrugAVT29 (proposed aflibercept HD biosimilar)

    Patients will receive IVT injections of AVT29

  • DrugAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive IVT injections of Eylea HD

06

What researchers measure

Primary outcomes

  1. Change from baseline to Week 8 in BCVA as measured by ETDRS letter score

    Time frame: week 8

07

Study locations

1 of 1 sites recruiting
  • Site 3004
    Budapest, Hungary
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 15 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 23, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jan 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07489131
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Apr 22, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Silvia Cirillo
Contact
alvotech.clinical@alvotech.com
+41 78 659 89 89

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion